Michael Merson joins AspenBio's board of directors
This article was originally published in Scrip
AspenBio Pharma (US), an emerging biopharmaceutical company developing drugs and diagnostics for humans and animals, has appointed Michael Merson as a new independent member of its board of directors. This appointment brings the total number of company directors to seven, with five serving independently. Mr Merson is a seasoned healthcare executive, having founded and managed several healthcare organisations, from hospitals to health insurers.
You may also be interested in...
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.
The Global Self-Care Federation is looking to consolidate the shift towards self-care seen during the pandemic by promoting trust, innovation and growth in policy. An upcoming webinar hosted by the GSCF will also explore the theme of "Advancing Trust in the Self-Care Industry."